Biocon surges 14% on USFDA nod for biosimilar of cancer drug
Shares of Biocon on Monday surged as much as 14 percent in morning trade after the biotechnology major said it has received regulatory approval to market a biosimilar of cancer drug Herceptin in the United States.
Dec 04, 2017, 12:17 PM IST